CG Oncology, Inc. (CGON)
(Delayed Data from NSDQ)
$31.88 USD
+1.05 (3.41%)
Updated Jul 5, 2024 04:00 PM ET
After-Market: $31.88 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CGON 31.88 +1.05(3.41%)
Will CGON be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CGON based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CGON
How to Find Up-and-Coming Stocks to Buy Right Now
CGON: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for CGON
A Closer Look at 9 Analyst Recommendations For CG Oncology
CG Oncology initiated with Buy on bladder cancer potential at BofA
CG Oncology initiated with bullish view at BofA
CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec
CG Oncology initiates EAP for Cretostimogene Grenadenorepvec in U.S.